Manel Kraiem Merabet
Chief Development Officer SKYMAB Biotherapeutics
Seminars
Wednesday 3rd March 2027
From GPCR Biology to the Clinic: Advancing SKM104 MA L2, a Novel GPCR-Targeting ADC
4:15 pm
- Applying lessons learned from GPCR-directed ADC discovery programs to refine target selection, antibody engineering and translational strategy
- Overcoming challenges associated with receptor expression, internalization and tumor heterogeneity to unlock additional GPCR opportunities in oncology
- Progressing SKM104 MA L2 through integrated optimization of target biology, antibody properties and payload design
